PeptideDB

(Rac)-Moxifloxacin-d4

CAS: 2512220-27-6 F: C21H20D4FN3O4 W: 405.46

(Rac)-Moxifloxacin-d4 ((Rac)-BAY 12-8039-d4 (free base)) is deuterium labeled (Rac)-Moxifloxacin. (Rac)-Moxifloxacin ((R
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity (Rac)-Moxifloxacin-d4 ((Rac)-BAY 12-8039-d4 (free base)) is deuterium labeled (Rac)-Moxifloxacin. (Rac)-Moxifloxacin ((Rac)-BAY 12-8039 free base) is the isoform of Moxifloxacin Hydrochloride (HY-66011), which is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].
CAS 2512220-27-6
Formula C21H20D4FN3O4
Molar Mass 405.46
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Culley CM, et al. Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm. 2001 Mar 1;58(5):379-88. [3]. Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59(1):115-39. [4]. Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702. [5]. Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58(2):96-102.